Geron Corp (NASDAQ:GERN)

CAPS Rating: 3 out of 5

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

Recs

0
Player Avatar GTcollegekid (< 20) Submitted: 7/9/2011 10:21:24 AM : Outperform Start Price: $4.35 GERN Score: -66.87

stem cell

Featured Broker Partners


Advertisement